AB Science provides an update on the EMA timetable for examination of the masitinib marketing authorization application in ALS
18 sept. 2023 12h05 HE
|
AB Science
PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON THE EUROPEAN MEDICINES AGENCY'S TIMETABLE FOR EXAMINATION OF THE MARKETING AUTHORIZATION APPLICATION OF MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS ...
PathMaker Neurosystems Announces Initiation of First-in-Human Trial in ALS for Non-Invasive Neuromodulation Device
14 sept. 2023 06h00 HE
|
PathMaker Neurosystems Inc.
BOSTON and PARIS, Sept. 14, 2023 (GLOBE NEWSWIRE) -- PathMaker Neurosystems Inc. (“PathMaker”), a near-commercial stage neuromodulation company developing breakthrough non-invasive systems for the...
ZyVersa Therapeutics Announces Research Published in Frontiers in Immunology Reinforcing IC 100’s Rationale for Inhibiting Multiple Inflammasomes to Control Inflammation in Various Inflammatory Diseases
12 sept. 2023 06h30 HE
|
ZyVersa Therapeutics
Activation of multiple inflammasome pathways contributes to pathological inflammation in neurodegenerative (“CNS”) diseases, such as amyotrophic lateral sclerosis (“ALS”)This study showed that NLRP3...
Athira Pharma Reports Second Quarter 2023 Financial Results and Pipeline and Business Updates
10 août 2023 16h05 HE
|
Athira Pharma, Inc.
Completed end of Phase 2 meeting and continued engagement with U.S. Food and Drug AdministrationAppointed Andrew Gengos as Chief Financial Officer and Chief Business OfficerMaintains strong balance...
How High Is the Bar for Future ALS Treatments? Although Neurologists Express Frustration with Current Treatments, They Are Quick to Adopt Therapies that Promise to Delay ALS Progression
02 août 2023 11h15 HE
|
Spherix Global Insights
Exton, Pennsylvania, Aug. 02, 2023 (GLOBE NEWSWIRE) -- A quiet but significant advance was made during the last year: not one, but two medicines were FDA approved to delay disease progression in the...
Pasithea Therapeutics publishes study in Proceedings of the National Academy of Sciences (PNAS) that shows an increase in α5 integrin expression in ALS human and mouse brain tissue, and further demonstrates targeting α5 integrin results in improved survival and motor function
01 août 2023 07h59 HE
|
Pasithea
-- PAS-003 is a monoclonal antibody targeting α5/β1 integrin for the treatment of amyotrophic lateral sclerosis (“ALS”) -- -- Lead α5/β1 integrin drug candidate to be selected in H2 2023 -- ...
Amyotrophic Lateral Sclerosis Market to Surge Immensely by 2032, Predicts DelveInsight | Key Companies to Watch Out - Cytokinetics, Orphazyme, Orion, Biogen, AB Science, Ionis, Biohaven, MediciNova, NeuroSense
19 juil. 2023 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, July 19, 2023 (GLOBE NEWSWIRE) -- Amyotrophic Lateral Sclerosis Market to Surge Immensely by 2032, Predicts DelveInsight | Key Companies to Watch Out - Cytokinetics, Orphazyme, Orion,...
Spinogenix Receives Approval from the Australia Human Research Ethics Committee to Initiate a Phase 1 Human Clinical Trial of SPG302, a Novel Regenerative Drug for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
10 juil. 2023 05h00 HE
|
Spinogenix, Inc.
SAN DIEGO, July 10, 2023 (GLOBE NEWSWIRE) -- Spinogenix, Inc., a clinical-stage biopharmaceutical company developing novel small molecule drugs for neurological conditions, today announced that it...
Athira Pharma Announces Upcoming Presentations at the Alzheimer’s Association International Conference (AAIC) 2023
06 juil. 2023 07h00 HE
|
Athira Pharma, Inc.
BOTHELL, Wash., July 06, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
PathMaker Neurosystems Receives $200,000 START Award from MassVentures
05 juin 2023 06h00 HE
|
PathMaker Neurosystems Inc.
BOSTON, June 05, 2023 (GLOBE NEWSWIRE) -- PathMaker Neurosystems Inc. (“PathMaker”), a near-commercial stage neuromodulation company developing breakthrough non-invasive systems for the treatment of...